Hansa Biopharma AB (publ) HNSBF
3.29 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
2.93 Day range 2.93
2.90 52-week range 3.70
- YTD
- +13.02%
- 1 year
- +13.02%
News
prnewswire.com Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well…
defenseworld.net Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Increase in Short Interest Hansa Biopharma AB (publ) (OTCMKTS:HNSBF - Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 93,732…
prnewswire.com Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering Hansa is deploying Cradle's end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease. AMSTERDAM, Oct. 1, 2026 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA),…
prnewswire.com Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney…
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
prnewswire.com Hansa Biopharma participating in Wedbush PacGrow Renal Summit LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a…
prnewswire.com Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly…
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript
prnewswire.com Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile…
prnewswire.com Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been…
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript Hansa Biopharma AB (publ) (HNSBF) Discusses Out-Licensing Agreement With SERB for Idefirix Commercialization in Europe and MENA Transcript
prnewswire.com Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa's financial position, ensuring a robust U.S.…
globenewswire.com SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Q1 2026 Earnings Call Transcript Hansa Biopharma AB (publ) (HNSBF) Q1 2026 Earnings Call Transcript
defenseworld.net Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Down 15.6% in March Hansa Biopharma AB (publ) (OTCMKTS:HNSBF - Get Free Report) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 11,135 shares, a drop of…
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript
prnewswire.com Hansa Biopharma has won the 2025 SwedenBIO Award LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was…
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript Hansa Biopharma AB (publ) (OTC:HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases November 12, 2025 9:00 AM EST Company…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Lows On Thursday